RODRIGO DE HOLANDA MENDONCA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
- Muscle biopsy with dystrophic pattern and rimmed vacuoles: GNE myopathy in a Brazilian patient(2017) ESTEPHAN, Eduardo de Paula; MORENO, Cristiane Araujo Martins; SILVA, Andre Macedo Serafim da; MENDONCA, Rodrigo de Holanda; ABATH NETO, Osorio; NISHIMURA, Patricia Yoshi; GALINDO, Layla Testa; ZANOTELI, Edmar
conferenceObject SENSITIVITY OF NEUROPHYSIOLOGIC TESTS REGARDING THE NEUROMUSCULAR JUNCTION IN PATIENTS WITH CONGENITAL MYASTHENIC SYNDROMES(2019) CALDAS, Vitor Marques; ESTEPHAN, Eduardo de Paula; SILVA, Andre Macedo Serafim da; MENDONCA, Rodrigo de Holanda; HEISE, Carlos Otto; ZANOTELI, Edmar- Unilateral abdominal protrusion as the main diagnostic sign of facioscapulohumeral dystrophy(2019) SILVA, Andre Macedo Serafim da; CAVALCANTE, Wagner Cid Palmeira; CAMELO, Clara Gontijo; MENDONCA, Rodrigo de Holanda; FORTINI, Ida; CARVALHO, Mary Souza de; ZANOTELI, Edmar
conferenceObject Concentric Needle Voluntary Jitter Assessment in Patients with Mitochondrial Myopathy(2019) CALDAS, Vitor Marques; ESTEPHAN, Eduardo de Paula; SILVA, Andre Macedo Serafim da; MENDONCA, Rodrigo de Holanda; CARVALHO, Mary Souza de; HEISE, Carlos Otto; ZANOTELLI, Edmar- The Location of Disease-Causing DES Variants Determines the Severity of Phenotype and the Morphology of Sarcoplasmic Aggregates(2022) SILVA, Andre Macedo Serafim; RODRIGO, Patricia; MORENO, Cristiane Araujo Martins; MENDONCA, Rodrigo de Holanda; ESTEPHAN, Eduardo de Paula; CAMELO, Clara Gontijo; CAMPOS, Eliene Dutra; DIAS, Alexandre Torchio; NASCIMENTO, Amom Mendes; KULIKOWSKI, Leslie Domenici; OLIVEIRA, Acary Souza Bulle; REED, Umbertina Conti; GOLDFARB, Lev G.; OLIVE, Montse; ZANOTELI, EdmarDesmin (DES) is the main intermediate muscle filament that connects myofibrils individually and with the nucleus, sarcolemma, and organelles. Pathogenic variants of DES cause desminopathy, a disorder affecting the heart and skeletal muscles. We aimed to analyze the clinical features, morphology, and distribution of desmin aggregates in skeletal muscle biopsies of patients with desminopathy and to correlate these findings with the type and location of disease-causing DES variants. This retrospective study included 30 patients from 20 families with molecularly confirmed desminopathy from 2 neuromuscular referral centers. We identified 2 distinct patterns of desmin aggregates: well-demarcated subsarcolemmal aggregates and diffuse aggregates with poorly delimited borders. Pathogenic variants located in the 1B segment and the tail domain of the desmin molecule are more likely to present with early-onset cardiomyopathy compared to patients with variants in other segments. All patients with mutations in the 1B segment had well-demarcated subsarcolemmal aggregates, but none of the patients with variants in other desmin segments showed such histological features. We suggest that variants located in the 1B segment lead to well-shaped subsarcolemmal desmin aggregation and cause disease with more frequent cardiac manifestations. These findings will facilitate early identification of patients with potentially severe cardiac syndromes.
- Child Neurology: A Case of FHL1-Related Disease Presenting as Inflammatory Myopathy(2021) SILVA, Andre Macedo Serafim; CAMELO, Clara Gontijo; MATSUI-JUNIOR, Ciro; MENDONCA, Rodrigo de Holanda; CAMPOS, Lucia Maria; ELIAS, Adriana Maluf; SILVA, Clovis Artur; REED, Umbertina Conti; ZANOTELI, Edmar
- Managing intrathecal administration of nusinersen in adolescents and adults with 5q-spinal muscular atrophy and previous spinal surgery(2021) MENDONCA, Rodrigo de Holanda; FERNANDES, Hermann Dos Santos; PINTO, Rafael Barbero Schimmelpfeng; MATSUI JUNIOR, Ciro; POLIDO, Graziela Jorge; SILVA, Andre Macedo Serafim da; GROSSKLAUSS, Luis Fernando; REED, Umbertina Conti; ZANOTELI, EdmarBackground: Spinal muscular atrophy (SMA) is a neurodegenerative disease of lower motor neurons associated with frequent occurrence of spinal deformity. Nusinersen is an antisense oligonucleotide that increases SMN protein level and is administrated by frequent intrathecal lumbar injections. Thus,spinal deformities and previous spinal surgery are important challenges for drug delivery in SMA.Objective: To report imaging methods used for Nusinersen injection in SMA patients. Methods: Nusinersen injection procedures in SMA types 2 and 3 patients who had previous spinal surgery were analyzed retrospectively to describe the imaging and puncture procedures, as well as the occurrence of complications. Results: Nine SMA patients (14 to 50 years old) underwent 57 lumbar punctures for nusinersen injection. Six patients had no interlaminar space available; in five of them, a transforaminal approach was used, and another one underwent a surgery to open a posterior bone window for the injections. Transforaminal puncture was performed using CT scan in three cases and fluoroscopy in the other two, with a similar success rate. One patient in the transforaminal group had post-procedure radiculitis, and another one had vagal reaction (hypotension). In three cases, with preserved interlaminar space, injections were performed by posterior interlaminar puncture, and only one adverse event was reported (post-puncture headache). Conclusion: In SMA patients with previous spinal surgery, the use of imaging-guided intervention is necessary for administering intrathecal nusinersen. Transforaminal technique is indicated in patients for whom the interlaminar space is not available, and injections should always be guided by either CT or fluoroscopy.
- Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy(2020) MENDONCA, Rodrigo de Holanda; JR, Ciro Matsui; POLIDO, Graziela Jorge; SILVA, Andre Macedo Serafim; KULIKOWSKI, Leslie; DIAS, Alexandre Torchio; ZANARDO, Evelin Aline; SOLLA, Davi Jorge Fontoura; GURGEL-GIANNETTI, Juliana; MOURA, Ana Carolina Monteiro Lessa de; SAMPAIO, Gabriela Palhares Campolina; OLIVEIRA, Acary Souza Bulle; SOUZA, Paulo Victor Sgobbi de; PINTO, Wladimir Bocca Vieira de Rezende; GONCALVES, Eduardo Augusto; FARIAS, Igor Braga; NARDES, Flavia; ARAUJO, Alexandra Prufer de Queiroz Campos; JR, Wilson Marques; TOMASELLI, Pedro Jose; RIBEIRO, Mara Dell Ospedale; KITAJIMA, Joao Paulo; MONTEIRO, Fabiola Paoli; SAUTE, Jonas Alex Morales; BECKER, Michele Michelin; SARAIVA-PEREIRA, Maria Luiza; BRUSIUS-FACCHIN, Ana Carolina; LINDEN, Vanessa van der; FLORENCIO, Rodrigo Neves; BARBOSA, Andre Vinicius Soares; MACHADO-COSTA, Marcela Camara; PESSOA, Andre Luiz Santos; SOUZA, Leticia Silva; JR, Marcondes Cavalcante Franca; KOK, Fernando; REED, Umbertina Conti; ZANOTELI, EdmarObjective The aim of the study was to report the proportion of homozygous and compound heterozygous variants in the survival motor neuron 1 (SMN1) gene in a large population of patients with spinal muscular atrophy (SMA) and to correlate the severity of the disease with the presence of specific intragenic variants in SMN1 and with the SMN2 copy number. Methods Four hundred fifty Brazilian patients with SMA were included in a retrospective study, and clinical data were analyzed compared with genetic data; the SMN2 copy number was obtained by multiplex ligation-dependent probe amplification and pathogenic variants in SMN1 by next-generation sequencing. Results Four hundred two patients (89.3%) presented homozygous exon 7-SMN1 deletion, and 48 (10.7%) were compound heterozygous for the common deletion in one allele and a point mutation in the other allele. Recurrent variants in exons 3 and 6 (c.460C>T, c.770_780dup and c.734_735insC) accounted for almost 80% of compound heterozygous patients. Another recurrent pathogenic variant was c.5C>G at exon 1. Patients with c.770_780dup and c.734_735insC had a clinical phenotype correlated with SMN2 copy number, whereas the variants c.460C>T and c.5C>G determined a milder phenotype independently of the SMN2 copies. Conclusions Patients with specific pathogenic variants (c.460C>T and c.5C>G) presented a milder phenotype, and the SMN2 copy number did not correlate with disease severity in this group.
- Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen(2021) MENDONCA, Rodrigo de Holanda; POLIDO, Graziela Jorge; MATSUI JR., Ciro; SOLLA, Davi Jorge Fontoura; REED, Umbertina Conti; ZANOTELI, EdmarBackground: Spinal muscular atrophy type 1 (SMA1) is a motor neuron disease associated with progressive muscle weakness, ventilatory failure, and reduced survival. Objective: To report the evaluation of the nusinersen, an antisense oligonucleotide, on the motor function of SMA1. Methods: This was a longitudinal and observational study to assess the outcomes of nusinersen therapy in SMA1 patients using the HINE-2 and CHOP-INTEND scales. Results: Twenty-one SMA1 patients (52.4% males) were included; the mean age at first symptoms was 2.7 months (SD = +/- 1.5), and the mean disease duration at first dose was 34.1 (SD = +/- 36.0) months. During posttreatment, the mean gain on the CHOP-INTEND was 4.9, 5.9, 6.6, and 14 points after 6, 12, 18, and 24 months, respectively. Starting medication with a disease duration of less than 12 months and/or without invasive ventilation were predictors of response on CHOP-INTEND. Of the patients, 28.6% acquired a motor milestone or gained at least three points on the HINE-2. The daily time for ventilatory support was reduced after treatment in most of the patients with noninvasive ventilation at baseline. No change in the daytime use of ventilation was observed in most of the patients using invasive ventilation at baseline. Conclusions: Nusinersen produces improvements in motor and respiratory functions, even in long-term SMA1 patients. However, patients under invasive ventilation at the beginning of the treatment experience little benefit.
- Facial and bulbar muscle atrophy in acetylcholine receptor antibody-positive myasthenia gravis(2017) GRATIVVOL, Ronnyson Susano; SILVA, Andre Macedo Serafim da; GUEDES, Brino Fukelmann; ESTEPHAN, Eduardo de Paula; MENDONCA, Rodrigo de Holanda; ZAMBON, Antonio Alberto; HEISE, Carlos Otto; ZANOTELI, Edmar